Latest news with #SOUL
Yahoo
a day ago
- Entertainment
- Yahoo
Off the Grid: Sally breaks down USA TODAY's daily crossword puzzle, Starter Homes
There are spoilers ahead. You might want to solve today's puzzle before reading further! Starter Homes Constructor: Sala Wanetick Editor: Jared Goudsmit APPLE (1A: "I guess the ___ don't fall far from the tree" (Charli XCX lyric)) "I guess the APPLE don't fall far from the tree" is a line from Charli XCX's 2024 song "APPLE." This is a fun clue, because fans of Charli XCX will enjoy seeing the song referenced. However, the answer is still gettable for solvers not familiar with Charli XCX, since "the APPLE doesn't fall far from the tree" is a common idiom. ABBA (6A: "Mamma Mia" group) Mamma Mia is a jukebox musical featuring the songs of ABBA. I've seen Mamma Mia multiple times, both the stage production and the movie adaptation. As I was refreshing my memory about which ABBA songs were included in Mamma Mia, I noticed that ABBA favored repetition in their song titles: "Honey, Honey," "Money, Money, Money," "Gimme! Gimme! Gimme!," and "I Do, I Do, I Do, I Do, I Do." SOLID (13A: Like Mercury, but not mercury) Mercury (with a capital M) is a SOLID, rocky planet. However, mercury (with a lowercase m) is a silvery element that is a liquid (therefore not a SOLID) at standard temperature and pressure. I quite like this somewhat science-y clue. ALI (16A: Academy Award winner Mahershala) Mahershala ALI has won two Academy Awards for Best Supporting Actor. In 2017, he received an Academy Award for his portrayal of Juan (a drug dealer who becomes a father figure to the film's main character) in the movie Moonlight. In 2019, Mahershala ALI received an Academy Award for his portrayal of Don Shirley (an African American pianist who hires an Italian American bouncer – played by Viggo Mortensen – as his driver) in the biographical movie Green Book. THC (21A: Psychoactive ingredient in pot brownies) Tetrahydrocannabinol, or THC, is the active ingredient in many weed gummies and other cannabis-infused edibles such as pot brownies. THC can induce a range of effects including, relaxation, euphoria, heightened sensory perception, and either decreased or increased anxiety. OSCAR (31A: Muppet who lives in a trash can) I'm a fan of the curmudgeonly OSCAR the Grouch who lives in a trash can on Sesame Street. OSCAR was originally performed by puppeteer Caroll Spinney (1933-2019), who also played Big Bird. Since 2018, OSCAR has been performed by Eric Jacobson. FUN (43A: "All I wanna do is have some ___ / I got a feelin' I'm not the only one" (Sheryl Crow lyric)) "All I Wanna Do" is a 1994 song by Sheryl Crow. "All I wanna do is have some FUN / I got a feelin' I'm not the only one..." Here's my FUN fact about Sheryl Crow: In the early 1980s, we both lived in Columbia, Missouri (though we didn't know each other). Sheryl Crow was a student at the University of Missouri at that time, and I was attending high school. SOUL (44A: 2020 Pixar film about a jazz musician) SOUL is a 2020 Pixar movie. The animated film focuses on the life of Joe Gardner (voiced by Jamie Foxx), a part-time music teacher who dreams of playing jazz full-time. After Joe's SOUL and body are accidentally separated, he must find a way to reunite them. SOUL won Academy Awards for Best Animated Feature and Best Original Score. TNT (45A: "Inside the NBA" channel) Inside the NBA is a TNT show that does halftime and postgame analysis of NBA games. The show is hosted by Ernie Johnson, and analysis is currently provided by Charles Barkley, Shaquille O'Neal, and Kenny Smith. EGGS (50A: Masala omelet ingredients) A masala omelet is an omelet variation associated with Indian cuisine. The main ingredients of the dish are EGGS, onions, green chilies, and tomatoes. MALI (56A: Landlocked West African country) MALI is (as the clue informs us) a landlocked country in West Africa. MALI is bordered by Algeria, Niger, Mauritania, Burkina Faso, Ivory Coast, Guinea, and Senegal. The capital of MALI is Bamako. MACAROON (10D: Cookie often eaten during Passover) A MACAROON is a mounded cookie made with egg whites, sugar, and ground almonds; it often contains coconut. MACAROONs may be eaten during the Jewish holiday Passover, since they are kosher and do not contain leavening or flour. ASS (35D: Mule's dad) A mule is the offspring of a male donkey (aka ASS) and a female horse. GAMING (51D: Playing Minecraft, say) Minecraft is a sandbox game, a video game in which players have a chance to be creative and explore the world without a set objectives to accomplish. While GAMING, players can discover and extract raw materials, craft tools, and build things. SITTER (53D: Person looking after pets) My cat, Willow, is not a fan of being left with a SITTER, and she always has a lot to say about it afterwards. LGA (64D: Airport near JFK) John F. Kennedy International Airport (JFK) and LaGuardia Airport (LGA) both serve the New York City (NYC) Metropolitan area. Both JFK and LGA are located in the NYC borough of Queens, about 10 miles apart from each other. OBI (65D: ___-Wan Kenobi) This clue has me wondering which Star Wars character shows up in crosswords most often. Is it OBI-Wan Kenobi, Han Solo, Princess Leia, Yoda, Luke Skywalker...? A few other clues I especially enjoyed: PLURAL (3D: Like "geese" and "cacti") ABACUS (6D: Calculator with beads) HULA HOOP (39D: Round toy that's twirled) STUDIO AUDIENCES (17A: Sitcoms are often filmed in front of them) HOUSE DRESSING (39A: Part of a restaurant's standard salad) LODGE A COMPLAINT (64A: Gripe to the manager, say) STARTER HOMES: The first, or STARTER, word of each theme answer is a type of HOME: STUDIO, HOUSE, and LODGE. Make yourself at HOME, whether you live in a STUDIO, a HOUSE, or a LODGE. I particularly enjoy the fact that each type of HOME does not mean HOME in the theme answer. Thank you, Sala, for this interesting puzzle. USA TODAY's Daily Crossword Puzzles Sudoku & Crossword Puzzle Answers This article originally appeared on USA TODAY: Crossword Blog & Answers for June 4, 2024 by Sally Hoelscher
Zawya
13-05-2025
- Business
- Zawya
Vision Developments launches "REEM" and "SOUL" in Dubai
Masoud Al Zarooni: We are committed to supporting Dubai's urban renaissance with exceptional ownership plans Dubai, United Arab Emirates: Vision Developments, one of the leading UAE real estate developers, announced the launch of two new residential projects, "REEM" and "SOUL," in Dubai. The move is part of their strategic expansion plan into several promising areas in the emirate and provide housing solutions that meet the aspirations of various segments of society. The "REEM" project is located in Liwan area, near Dubai Silicon Oasis and Academic City, with strategic access to Dubai's most prominent educational and technology destinations. It consists of a residential building with a commercial ground floor spanning 8,100 square feet, a parking floor, eight typical floors, and a roof (G+P+8F+R), comprising a total of 198 spacious residential units. The "SOUL" project, located in Dubai Production City, offers a vibrant lifestyle that combines comfort and community connectivity, while being close to Dubai Sports City and Jumeirah Golf Estates. The project consists of a nine-story building and a roof (G+9F+R), comprising 176 residential units. The two projects offer a wide range of amenities, including an Infinity swimming pool, gym, yoga, cinema, indoor and outdoor children's play areas, gaming room, a dedicated children's pool, barbecue area, party hall, and office spaces. The two projects are expected to be handed over in Q4 2026, with construction works already started. 'These projects embody the company's vision of building distinct and accessible residential communities,' said Engineer Masoud Al Zarooni, Co-Founder and CEO of Vision Developments. He noted that the company aims not only to provide residential units, but also to create living communities harmonizing people's lives and reflect their aspirations. "These new projects add to Vision Developments success story of completing and delivering a number of projects in Liwan area within a short period of time, including: Vision 1, Vision 2, Karma, and Platinum' said AL Zarooni. The company is currently working on several other projects in distinct areas such as Liwan, Dubai Silicon Oasis, Jumeirah Garden City, and Dubai Production City, including: Pearls, Celine, Coral, DGM, and Vision 5 Tower. Some are scheduled for delivery by the end of this year, and others by the end of next year. The total area of these projects exceeds 2 million Sq. Ft. and includes 1,193 residential units, 487 of which have already been handed over. "Within the company, we are committed to implementing and delivering projects according to the highest standards of quality and punctuality, through our executive arm 'Vision Construction', which represents one of the main pillars of our success,' he added. 'We are also proud of our close partnership and cooperation with our founding partners, Walid Owais and Ismail Abdullah, who together form a leadership team with extensive experience, and a unified vision focused on innovation and excellence at every stage of development," the CEO said. Al Zarooni confirmed Vision Developments commitment to supporting the sustainable urban renaissance in the Emirate of Dubai and actively contributing to shaping the future of the emirate's real estate market, especially with the exceptional payment plans consisting of a 20% down payment and 80% upon completion. This contributes to increased demand through competitive prices that facilitate easy property ownership.
Yahoo
30-03-2025
- Health
- Yahoo
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1. Data were presented at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, US, while simultaneously published today in New England Journal of Medicine2. Rybelsus®, the only approved oral GLP-1 medicine, demonstrated this risk reduction on top of standards of cardiovascular and diabetes care. Based on SOUL findings, Novo Nordisk submitted a label extension application for Rybelsus® for CV event risk reduction to the US FDA and EMA. Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD)1. These new data from the phase 3b trial were featured during a late-breaking clinical trial session at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, US and simultaneously published today in New England Journal of Medicine2. The SOUL trial achieved its primary endpoint, demonstrating a 14% reduction in risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and CVD and/or CKD when treated with Rybelsus® compared to placebo. Each component of MACE, being CV death, nonfatal myocardial infarction and nonfatal stroke, contributed to the risk reduction1. 'Heart attacks and strokes are the leading causes of disability and death for people with type 2 diabetes, and there is a need for new, patient-centric treatments to help manage this risk,' said Darren McGuire, MD, Distinguished Chair in Cardiovascular Science and Teaching Professor of Medicine at UT Southwestern, US, and SOUL steering committee co-chair. 'The SOUL trial in adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or CKD demonstrated significant reductions in the risk of major cardiovascular events including heart attack, stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound clinical impact for our patients who now have an oral option to improve health outcomes.' Cardiometabolic diseases span a wide range of conditions, including cardiovascular and peripheral artery disease, type 2 diabetes and chronic kidney disease3. When combined, these conditions represent the leading cause of death globally4. Having type 2 diabetes directly increases the risk of developing interconnected cardiometabolic diseases, while also contributing to the progression of other cardiovascular risk factors5. Nearly one in three adults with type 2 diabetes have CVD6. 'Novo Nordisk continues to evolve its focus beyond diabetes and obesity towards a broader spectrum of metabolic and cardiovascular health,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'These data, alongside our other data being presented at ACC, reinforce the comprehensive set of health benefits of semaglutide, making it a strong option for healthcare professionals addressing the spectrum of metabolic and cardiovascular health – and our continued leadership in the space.' The overall safety profile of oral semaglutide in SOUL was consistent with that seen in previous semaglutide trials, and no new safety signals were observed. The incidence of serious adverse events (SAEs) was lower in participants receiving Rybelsus® than those receiving placebo, mostly due to the higher rate of cardiovascular events and infections in the placebo group. The most common SAEs were cardiac disorders (17.8% and 19.8%, respectively) and infections/infestations (15.0% and 16.5%, respectively) in the Rybelsus® and placebo arms1. In a key secondary analysis from SOUL published simultaneously, oral semaglutide reduced risk of MACE independently of baseline use of SGLT2i and suggests similar benefits in participants with and without concomitant SGLT2i use during trial7. SOUL confirmed the well-established safety and tolerability profile of semaglutide supported by long-term safety data with more than 33 million patient years8. Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus®, which has been accepted for review by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA. A decision is anticipated in 2025. About SOUL SOUL was a multicentre, international, randomised, double-blind, parallel-group, placebo-controlled, phase 3 cardiovascular outcomes trial with 9,650 people enrolled. It was conducted to assess the effect of oral semaglutide vs placebo on cardiovascular outcomes in people with type 2 diabetes and established CVD and/or CKD. The SOUL trial was initiated in 2019. The key objective of SOUL was to demonstrate that oral semaglutide lowers the risk of major adverse cardiovascular events (a composite endpoint consisting of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) compared to placebo, both added to standard of care in patients with type 2 diabetes and established CVD and/or CKD9,10. About Rybelsus®Rybelsus® (oral semaglutide) is a GLP-1 receptor agonist indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise11,12. Rybelsus® is administered once daily and is approved for use in three therapeutic dosages: 3 mg, 7 mg and 14 mg13,14. Rybelsus® offers superior blood glucose lowering vs Januvia® and Jardiance®13,14, together with consistent weight reduction13-15 and reduction in cardiometabolic risk factors15. Rybelsus® is currently commercially marketed in 45 countries. More than 2.1 million people with type 2 diabetes are currently being treated with Rybelsus® worldwide16. About Novo NordiskNovo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Ida Schaap Melvold +45 3077 5649 idmg@ Sina Meyer +45 3079 6656 azey@ Max Ung+45 3077 6414mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ _______________________References1. McGuire DK, et al. Oral presentation presented at the American College of Cardiology Congress Scientific Session & Expo 2025; 29–31 March 2025. Presentation 104-07.2. McGuire DK., et al. N Engl J Med. 2025, New England Journal of Medicine: 3. Reiter-Brennan C, et al. Curr Cardiol Rep. 2021;23:22.4. World Health Organization [online]. Available at: Last accessed: February 2025.5. Chakraborty S, et al. Clin Med Insights Endocrinol Diabetes. 2023;16:11795514231220780.6. Mosenzon O, et al. Cardiovasc Diabetol. 2021;20:1547. Marx N., et al. Circulation 2025: Novo Nordisk data on file.9. NCT03914326. Available at: Last accessed: February 2025.10. McGuire DK, et al. Diabetes Obes Metab. 2023;25:1932–1941.11. Rybelsus® (semaglutide) US PI. 2024 [online]. Available at: Last accessed: March 2025.12. Rybelsus® (semaglutide) SmPC. 2025 [online]. Available at: Last accessed: March 2025.13. Rodbard HW, et al. Diabetes Care. 2019;42:2272–2281.14. Rosenstock J, et al. JAMA. 2019;321:1466–1480.15. Husain M, et al. N Engl J Med. 2019;381:841–851.16. Novo Nordisk Data on File. IQVIA Ozempic and Rybelsus patient numbers March 2025. Attachment PR250329-1930-ACC2025-SOULSign in to access your portfolio
Yahoo
30-03-2025
- Health
- Yahoo
Oral semaglutide 14 mg demonstrated superior reduction in risk of cardiovascular events in late-breaking SOUL trial presented at the American College of Cardiology
SOUL study showed Rybelsus® (semaglutide) tablets 14 mg reduced the risk of major adverse cardiovascular events (MACE) by 14% (ARR 2% absolute risk reduction at 3 years) vs placebo in adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD)1 Oral semaglutide 14 mg demonstrated this reduction of risk on top of standards of cardiovascular (CV) and diabetes care Data simultaneously published today in The New England Journal of Medicine, and based on SOUL findings, Novo Nordisk submitted a label extension application for Rybelsus® (semaglutide) tablets 14 mg for CV event risk reduction to the FDA PLAINSBORO, N.J., March 29, 2025 /PRNewswire/ -- Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial investigating the effects of Rybelsus® (semaglutide) tablets 14 mg on reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and ASCVD and/or CKD.1 These new data from the phase 3 trial were featured during a Late-Breaking Clinical Trial session at the American College of Cardiology's (ACC) Annual Scientific Session and Expo and simultaneously published today in The New England Journal of Medicine. The randomized, double-blind, parallel-group, placebo-controlled, event-driven CV outcomes trial which enrolled 9,650 adults with type 2 diabetes and ASCVD and/or CKD, achieved its primary endpoint, with oral semaglutide 14 mg demonstrating a 14% reduction in risk of MACE (2% absolute risk reduction at 3 years) compared to placebo (579 vs 668 events; hazard ratio: 0.86 [0.77; 0.96]; P=0.0055). The primary endpoint was time from randomization to first occurrence of a major adverse CV event (a composite of CV death, nonfatal myocardial infarction or nonfatal stroke).1,2 "The significant reduction in risk of composite endpoint of heart attack, stroke, or death seen in the SOUL trial in adults with type 2 diabetes highlights the cardiovascular impact of oral semaglutide in adult patients with cardiometabolic conditions such as type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease," said John B. Buse, MD, PhD, Distinguished Professor of Medicine, Director of UNC Diabetes Care Center, Steering Committee Co-Chair of the SOUL trial. "Given the cardiovascular outcomes seen in SOUL, the trial represents important data for a community who may need options that also address common and serious comorbidities of type 2 diabetes, like cardiovascular disease." Cardiometabolic diseases span a wide range of conditions, including type 2 diabetes and cardiovascular disease.3 Overall, cardiovascular disease represents the leading cause of death globally.4 Having type 2 diabetes directly increases the risk of developing interconnected cardiometabolic diseases, while also contributing to the progression of other cardiovascular risk factors.5,6 Nearly one in three adults with type 2 diabetes have cardiovascular disease (CVD).7 "Novo Nordisk continues to evolve its leadership beyond any one therapy area, toward a broader spectrum of cardiometabolic diseases that explores the interconnectivity of these conditions to create better outcomes for patients," said Michael Radin, MD, Executive Medical Director, Diabetes Medical Affairs at Novo Nordisk, Inc. "The SOUL data reinforce the importance of looking beyond glycemic control to explore cardiovascular disease in patients with type 2 diabetes." The overall safety profile of oral semaglutide 14 mg in SOUL was consistent with that seen in previous trials, and no new safety signals were observed. The incidence of serious adverse events (SAEs) was lower in participants receiving oral semaglutide 14 mg than those receiving placebo, mostly due to the higher rate of cardiovascular events and infections in the placebo group. The most common SAEs were cardiac disorders (17.8% and 19.8%, respectively) and infections/infestations (15.0% and 16.5%, respectively).1 Serious adverse events were less common with oral semaglutide 14 mg (47.9%) than with placebo (50.3%), although there was a higher incidence of gastrointestinal disorders with oral semaglutide 14 mg (5.0% versus 4.4%). Adverse events leading to permanent treatment discontinuation were more common for oral semaglutide 14 mg than placebo (749 [15.5%] and 559 [11.6%], respectively), comprising mainly gastrointestinal disorders in both arms (310 [6.4%] and 98 [2.0%], respectively). Additionally, the placebo group had 96 cases (2.0%) of infections and infestations leading to treatment discontinuation (versus 63 [1.3%] with oral semaglutide 14 mg).1,2 Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus® (semaglutide) tablets 14 mg which has been accepted for review by the US Food & Drug Administration (FDA). A decision is anticipated in 2025.2 About SOUL SOUL was a multicenter, international, randomized, double-blind, parallel-group, placebo-controlled, event-driven phase 3 cardiovascular outcomes trial with 9,650 people enrolled. It was conducted to assess the effect of oral semaglutide 14 mg vs placebo on cardiovascular outcomes in adults with type 2 diabetes and ASCVD and/or CKD. SOUL included adults aged ≥50 years with type 2 diabetes and evidence of ASCVD (coronary artery disease [CAD], cerebrovascular disease, symptomatic peripheral arterial disease [PAD]) and/or CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2). The SOUL trial was initiated in 2019 with a total duration of 5 years and 2 months. The key objective of the SOUL trial was to demonstrate that oral semaglutide 14 mg helps lower the risk of major adverse cardiovascular events (a composite endpoint consisting of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) compared to placebo, both added to standard of care in patients with type 2 diabetes and ASCVD and/or CKD.8 About Rybelsus® Rybelsus® (semaglutide) tablets 7 mg and 14 mg is a once daily glucagon-like peptide-1 (GLP-1) receptor agonist indicated for adults with type 2 diabetes along with diet and exercise to improve glycemic control.9 Only Novo Nordisk manufactures FDA-approved semaglutide medicines, like Rybelsus®. Given the vast amount of information on knock-off or compounded semaglutide being shared in the media, it is important for healthcare professionals and patients to have the clarity and confidence in knowing what they are using has undergone rigorous review for safety, effectiveness and quality. If the label doesn't say Rybelsus®, it's not FDA-approved. Learn more about the responsible use of semaglutide-containing medicines and the significant safety and health risks associated with compounded or knock-off "semaglutide" at About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With U.S. headquarters in New Jersey and over ten manufacturing, R&D and business locations in eight states plus Washington DC, Novo Nordisk employs approximately 10,000 people throughout the country. For more information, visit Facebook, Instagram, and X. Contacts for further information: Media: Liz Skrbkova (US) +1 609 917 0632 lzsk@ Ambre James-Brown (Global)+45 3079 9289 abmo@ US Media Relations NNIMediaTeam@ Investors: Frederik Taylor Pitter (US) +1 609 613 0568 fptr@ Jacob Martin Wiborg Rode +45 3075 5956 jrde@ Sina Meyer+45 3079 6656 azey@ Ida Schaap Melvold +45 3077 5649 idmg@ Max Ung +45 3077 6414 mxun@ References McGuire DK, Poulter NR, Pop-Busui R, et al. Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial. Oral presentation presented at the American College of Cardiology Congress Scientific Session & Expo 2025; 29-31 March 2025; McCormick Place Convention Center, Chicago, US. Presentation 104-07. Data on file. Novo Nordisk, Inc.; Plainsboro, NJ. Reiter-Brennan C, Dzaye O, Davis D, et al. Comprehensive care models for cardiometabolic disease. Curr Cardiol Rep. 2021;23(3):22. Published 2021 Feb 24. doi:10.1007/s11886-021-01450-1. World Health Organization. Cardiovascular diseases (cvds). Accessed February 28, 2025. Feng X (Snow), Farej R, Dean BB, et al. CKD prevalence among patients with and without type 2 diabetes: regional differences in the United States. Kidney Medicine. 2022;4(1):100385. doi: Jankowski J, Floege J, Fliser D, Böhm M, Marx N: Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021, 143:1157-72. 10.1161/CIRCULATIONAHA.120.050686. Mosenzon O, Alguwaihes A, Leon JLA, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20:154. A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL). Available at: Last accessed: February 2025. Rybelsus® (semaglutide) tablets [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2024. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25RYB00225 March 2025 View original content: SOURCE Novo Nordisk, Inc. Sign in to access your portfolio
Yahoo
20-03-2025
- General
- Yahoo
Children's Alliance of Kansas to support SOUL Family foster care program with advisory group
Gov. Laura Kelly, during a May 14, 2024, celebration of SOUL Family legislation in Topeka, talks about her efforts to work with lawmakers to improve the state's child welfare system. (Sherman Smith/Kansas Reflector) TOPEKA — The Children's Alliance of Kansas will provide support for a new foster care program that expands placement options for teens by letting them stay with a family member or close friend. The SOUL Family program, which was created through legislation last year, provides teens 16 and older in foster care the opportunity to choose a non-family member to be their guardian, while still benefiting from foster care benefits. SOUL stands for Support, Opportunity, Unity, Legal Relationships. 'It gives youths the opportunity to define family in their own terms and create a route to permanency,' said KVC education and transition specialists supervisor Kim Duncan. 'SOUL is an opportunity for that to happen.' KVC is one of the agencies that contracts with the state to provide foster care services. The Annie E. Casey Foundation will provide a grant to the Children's Alliance to fund a SOUL Family advisory group with the Department for Children and Families and other child welfare organizations. The funds will help pay advisory group members with lived experience in foster care. 'We'll be focusing on how we assess progress that we're making, any insights that we have with youths who are navigating toward a SOUL family and just helping support the ongoing implementation and success of this project,' said Children's Alliance CEO Kristalle Hedrick. Gov. Laura Kelly made Kansas the first state to add the SOUL program to the options for permanency after signing the bill into law in April. According to data from DCF, seven teenagers in foster care have reached permanency through the program, from July to December of last year. Eight other case plans have been changed to SOUL and are in the process of being finalized. Foster teens who participate in SOUL are likely to spend less time in the foster care system. 'The Children's Alliance was a strong proponent of that legislation,' Hedrick said. 'One of the things that we're pretty proud of in the project is that we did raise the voices of young people and help them share what it's like for people who have left foster care.' Along with giving foster teens a choice in guardian, they also receive permanency benefits such as health care, educational support and an adult to help with what Hedrick calls 'day-to-day things' of life. 'A SOUL family relationship is designed to last throughout the kid's entire life, and it's recognized by the court for their whole life, so it doesn't have to stop at age 18, like custodianship does,' Hedrick said. 'Things are just really difficult to navigate adulthood. How do I pay my phone bill? How do I pay rent? This is an idea where several different adults from different households can step in and support youth.' Saint Francis Ministries, a foster care organization in Kansas, recorded the first official SOUL Family case in the state and the nation. 'Far too many young people leave foster care without a legal, supportive family,' said Holly Dean-Osborne, vice president of permanency at Saint Francis. 'By providing a permanency pathway that honors their identity and relationships, SOUL Family Legal Permanency ensures that every young person has the healing and hope they need to transition successfully into adulthood.'
